International Assets Investment Management LLC Sells 399 Shares of Stryker Corporation $SYK

International Assets Investment Management LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 17.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,853 shares of the medical technology company’s stock after selling 399 shares during the period. International Assets Investment Management LLC’s holdings in Stryker were worth $733,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of SYK. Nuveen LLC bought a new stake in Stryker during the first quarter valued at about $558,075,000. Price T Rowe Associates Inc. MD grew its holdings in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the period. Alliancebernstein L.P. grew its holdings in Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after purchasing an additional 549,643 shares during the period. Vanguard Group Inc. grew its holdings in Stryker by 1.1% during the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after purchasing an additional 361,136 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $381.27 on Tuesday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $145.76 billion, a P/E ratio of 50.50, a P/E/G ratio of 2.70 and a beta of 0.94. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The business’s 50-day moving average is $379.49 and its 200 day moving average is $379.09.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is 44.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Truist Financial dropped their price objective on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Wells Fargo & Company upped their price objective on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $431.76.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.